Key result
Trimetazidine significantly improved left ventricular diastolic function, reducing LVEDP (4.6 vs 11.5 mmHg) and cardiac fibrosis in streptozotocin-induced diabetic rats compared to vehicle.
Why the study?
Diabetes may affect myocardial fibrosis through oxidative stress, and whether trimetazidine modulates reactive oxygen species and connective tissue growth factor expression to improve diastolic function in diabetic rats was investigated.
Does trimetazidine reduce cardiac fibrosis and improve diastolic function in streptozotocin-induced diabetic rats?
Does trimetazidine reduce cardiac fibrosis and improve diastolic function in streptozotocin-induced diabetic rats?
Absolute Event Rate: 4.6% vs 11.5%
p-value: p=<0.05
Trimetazidine attenuates cardiac fibrosis and improves left ventricular diastolic function in diabetic rats by reducing reactive oxygen species and downregulating connective tissue growth factor.
Hypothesis-generating for trimetazidine in diabetic cardiomyopathy; should not change practice pending human trials.
Diabetes may affect myocardial fibrosis through oxidative stress. Trimetazidine (TMZ) is an anti‑anginal agent. The present study aimed to determine the modulatory effect of TMZ on reactive oxygen species (ROS) and connective tissue growth factor (CTGF) expression and to evaluate the potential of TMZ to improve diastolic function in streptozotocin (STZ)‑induced diabetic rats. After treating STZ‑induced diabetic rats with TMZ for 16 weeks, a decrease in malondialdehyde levels, cardiac collagen volume fraction, left ventricular (LV) end‑diastolic pressure and protein expression of collagen‑I (Col I), Col III and CTGF compared with those in diabetic control rats was observed. In vitro, TMZ inhibited Col I, Col III and CTGF protein expression in cardiac fibroblasts treated with high glucose and decreased intracellular ROS generation and hydroxyproline content in the cell culture medium of cardiac fibroblasts. TMZ markedly improved cardiac fibrosis and diastolic function in diabetic rats. This effect was associated with a reduction in ROS production and CTGF expression in cardiac fibroblasts. The present study suggests that TMZ may be beneficial for protecting the hearts of diabetic patients.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2019) studied Diabetic cardiomyopathy and cardiac fibrosis (n=40). Trimetazidine vs. Normal saline (vehicle) was evaluated on Left ventricular end-diastolic pressure (LVEDP) (p=<0.05). Trimetazidine significantly improved left ventricular diastolic function, reducing LVEDP (4.6 vs 11.5 mmHg) and cardiac fibrosis in streptozotocin-induced diabetic rats compared to vehicle.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: